Answers are grounded in this paper and cite their sources.
The emergence of clinically important mutations described in this report highlights the need for sustained vigilance and containment measures when managing immunocompromised patients with persistent COVID-19. Even as jurisdictions across the globe start lifting pandemic control measures, immunocompromised patients with persistent COVID-19 constitute a unique group that requires close genomic monitoring and enhanced infection control measures, to ensure early detection and containment of mutations and variants of therapeutic and public health importance.
No takes yet. Share an insight, caveat, or question.
Ko et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: